Home › Bronchopulmonary Dysplasia › NCT07417111
Continued Pressure for Alveolar Protection (CPAP Trial)
Recruiting
Continued Pressure for Alveolar Protection: A Randomized Controlled Trial (CPAP Trial)
Who can join
31 Weeks · All sexes
Full eligibility criteria
Inclusion Criteria: * Gestational age \<29 weeks at birth * PMA \<32 weeks at study entry * On treatment with CPAP without a rate in FiO2 \<0.25 and PEEP of 4-5 cmH2O * Meet stability criteria: * If previously intubated must be extubated ≥ 72 hours * \<3 self-resolving apneas (≤ 20 s) and/or bradycardia (\<100 bpm) in any hour over previous 6 hours * No episodes of apnea or bradycardia requiring intervention (oxygen/stimulation/bag and mask) for 24 hours * Parents/legal guardians consent for enrollment Exclusion Criteria: * Major malformation * Neuromuscular condition that affects respiration * Terminal illness * Decision to withhold or limit support * Too sick to participate in opinion of Attending physician * Clinical shock, sepsis * Planned surgery during study period
About the study
The objective of the CPAP Trial is to test whether extending CPAP until 34 weeks' PMA or for at least 2 additional weeks compared to weaning to a nasal canula will decrease the likelihood of bronchopulmonary dysplasia or death at 36 weeks' PMA.
What is being tested
- CPAP (device)
- Nasal Cannula (device)
Sponsor: NICHD Neonatal Research Network · Participants: 860 · Started: Nov 5, 2026
Contact the study team
- Colm P. Travers, MD · Phone: 205-934-3100
- Abhik Das, PhD · Phone: 301-230-4640
Official record on ClinicalTrials.gov — NCT07417111
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.